Heart Transplant in India and UAE | Complete Patient Guide

• ELIGIBILITY — MEDICAL INDICATIONS:

• End-stage heart failure (NYHA Class III–IV) with persistent symptoms despite optimal medical therapy (OMT) for ≥ 3 months

• Left ventricular ejection fraction (LVEF) ≤ 25–30% with high predicted 1-year mortality (HeartMate II Risk Score, HFSS, or MAGGIC score)

• Ischemic cardiomyopathy, dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, or complex congenital heart disease not amenable to conventional repair

• Refractory ventricular arrhythmias unresponsive to antiarrhythmic therapy or ICD

• Refractory angina or ischemia not amenable to revascularization (PCI or CABG)

• Peak VO₂ (cardiopulmonary exercise test) < 12 mL/kg/min (or < 14 mL/kg/min if beta-blocker intolerant)

• Dependence on continuous inotropic support or LVAD (bridge-to-transplant strategy)

• REQUIRED DIAGNOSTIC WORK-UP (PRE-TRANSPLANT EVALUATION):

• Echocardiogram (transthoracic and transoesophageal): Assessment of LVEF, wall motion, valve pathology, right heart function

• Right heart catheterization: Pulmonary artery pressures, pulmonary vascular resistance (PVR), transpulmonary gradient (TPG), cardiac index — PVR < 5 Wood units is typically required

• Coronary angiography: Delineate ischemic burden

• Cardiopulmonary exercise test (CPET): Peak VO₂, VE/VCO₂ slope

• 24-hour Holter monitoring and ECG

• PET-CT cardiac viability scan (where applicable, especially in ischemic cardiomyopathy)

• Full laboratory panel: CBC, comprehensive metabolic panel, renal and hepatic function, coagulation, lipid profile, HbA1c

• Serological screening: HIV, Hepatitis B & C, CMV, EBV, Toxoplasma, TB (Quantiferon-Gold)

• ABO blood typing, HLA typing, panel-reactive antibody (PRA) testing, prospective crossmatch

• Pulmonary function tests (PFTs) and chest CT

• Renal ultrasound and GFR calculation

• Cancer screening: Age-appropriate (colonoscopy, PSA, mammography, cervical smear)

• Psychosocial assessment: Psychiatric evaluation, substance abuse history, social support systems, medication adherence assessment

• Dental clearance: Active dental infection must be resolved pre-transplant

• ABSOLUTE CONTRAINDICATIONS:

• Fixed (irreversible) pulmonary hypertension: PVR > 5 Wood units unresponsive to vasodilator challenge (nitric oxide, epoprostenol)

• Active or recently treated malignancy (generally cancer-free interval of 2–5 years required, depending on tumor type)

• Systemic infection or untreated sepsis

• Active substance abuse (alcohol, illicit drugs)

• Severe, irreversible non-cardiac organ dysfunction (advanced cirrhosis, severe COPD — FEV1 < 40% predicted, dialysis-dependent renal failure without simultaneous kidney transplant consideration)

• Severe cerebrovascular or peripheral vascular disease limiting rehabilitation

• Morbid obesity (BMI > 35 kg/m² — center-specific threshold)

• Active psychiatric illness precluding informed consent or post-transplant adherence

• RELATIVE CONTRAINDICATIONS (INDIVIDUALIZED ASSESSMENT):

• Age > 70 years (center-specific; highly individualized)

• Diabetes mellitus with significant end-organ damage (nephropathy, retinopathy, severe neuropathy)

• Creatinine > 2.5 mg/dL or GFR < 40 mL/min (simultaneous heart-kidney transplant may be considered)

• Prior cardiac surgery (increases surgical complexity but is not prohibitive)

• High PRA (> 25%): Requires desensitization protocols; virtual crossmatch technology increasingly utilized

STANDARD ORTHOTOPIC HEART TRANSPLANTATION (OHT) — BIATRIAL vs. BICAVAL TECHNIQUE:

The bicaval technique (Sarsam-Yacoub modification) has largely supplanted the classic biatrial technique (Lower-Shumway) at high-volume centers. In the bicaval approach, the donor superior and inferior venae cavae are anastomosed directly to the recipient's own caval remnants, preserving right atrial geometry, sinus node function, and reducing the incidence of tricuspid regurgitation and post-operative arrhythmias (particularly atrial flutter). The surgical sequence involves median sternotomy, cardiopulmonary bypass (CPB) with cardioplegic arrest, cardiectomy (leaving posterior left atrial cuff and pulmonary veins), followed by sequential anastomosis of the donor left atrium (or individual pulmonary veins), inferior vena cava, superior vena cava, pulmonary artery, and ascending aorta. Cold ischemic time must be minimized — ideally < 4–6 hours — to reduce primary graft dysfunction (PGD).

HETEROTOPIC HEART TRANSPLANTATION (PIGGYBACK TECHNIQUE):

Rarely performed (< 2% of transplants globally), this technique places the donor heart in parallel with the recipient's native heart in the right hemithorax. It is reserved for patients with severe, irreversible pulmonary hypertension (elevated but not fixed PVR) where the donor right ventricle alone may be unable to sustain pulmonary circulation, allowing the native right ventricle to assist with pulmonary vascular load. It is also considered when donor heart size is significantly smaller than the recipient.

SIMULTANEOUS HEART-KIDNEY TRANSPLANTATION (HKT):

Increasingly performed at tertiary centers in India and the UAE for patients with combined end-stage heart failure and chronic kidney disease (eGFR < 30 mL/min). Studies demonstrate superior renal graft survival in the context of immunosuppression shared between both organs. A single donor provides both organs; surgical teams operate simultaneously.

MECHANICAL CIRCULATORY SUPPORT AS BRIDGE TO TRANSPLANT (BTT):

• HeartMate 3 LVAD (Abbott): Full magnetically levitated centrifugal-flow pump; currently the preferred BTT device. FDA-approved; reduces pump thrombosis and stroke rates compared to prior generations.

• HeartWare HVAD: Centrifugal-flow miniaturized device; while still implanted in some centers, production has been discontinued — HeartMate 3 is now standard.

• Intra-Aortic Balloon Pump (IABP) and Impella CP/5.5: Used for short-term hemodynamic stabilization in acute decompensation prior to LVAD implantation or direct listing.

• Veno-Arterial ECMO (VA-ECMO): Used in cardiogenic shock as a bridge to decision — bridge to recovery, bridge to LVAD, or bridge to transplant.

IMMUNOSUPPRESSION PROTOCOLS (STANDARD OF CARE):

• Induction: Basiliximab (IL-2 receptor antagonist) or rabbit anti-thymocyte globulin (rATG) in sensitized patients (PRA > 25%)

• Maintenance triple therapy: Tacrolimus (target trough 10–15 ng/mL in first year, then 8–12 ng/mL) + Mycophenolate mofetil (MMF, 1500 mg twice daily) + Prednisolone (tapering to 5 mg/day by 6 months; steroid withdrawal considered at 12 months in low-risk patients)

• mTOR inhibitors (Everolimus, Sirolimus): Introduced at 1–3 years post-transplant to allow tacrolimus dose reduction, provide renal-sparing benefit, and reduce cardiac allograft vasculopathy (CAV)

• CMV prophylaxis: Valganciclovir (standard in CMV D+/R- combinations for 6–12 months)

• PCP prophylaxis: Trimethoprim-sulfamethoxazole for 6–12 months

• Aspirin 81 mg daily: Commenced post-transplant for CAV prevention

REJECTION SURVEILLANCE AND MANAGEMENT:

• Endomyocardial biopsy (EMB): Gold-standard for rejection surveillance; performed weekly for first month, then tapering frequency per protocol. Graded per ISHLT 2004 criteria (0R, 1R, 2R, 3R for cellular rejection; pAMR 0–3 for antibody-mediated rejection)

• Non-invasive alternatives: Gene expression profiling (AlloMap®, CareDx) — validated for low-risk rejection surveillance at > 6 months post-transplant; reduces biopsy frequency

• Donor-derived cell-free DNA (dd-cfDNA) assay (AlloSure®): Emerging non-invasive liquid biopsy tool for real-time rejection monitoring

• Treatment of acute cellular rejection (≥ 2R): High-dose IV methylprednisolone (1 g/day × 3 days); refractory cases treated with rATG

• Treatment of antibody-mediated rejection (AMR): Plasmapheresis, IVIG, rituximab, and/or bortezomib depending on severity

CARDIAC ALLOGRAFT VASCULOPATHY (CAV) SURVEILLANCE:

• Annual coronary angiography from Year 1 post-transplant

• Intravascular ultrasound (IVUS): More sensitive than angiography for early CAV detection; recommended at Year 1 as baseline

• Optical coherence tomography (OCT): Increasing utilization at advanced centers

• Treatment: Everolimus/Sirolimus (antiproliferative + immunosuppressive); PCI for focal lesions; re-transplantation for severe, diffuse CAV

PHASE 1 — INITIAL EVALUATION AND LISTING (Weeks 1–4 prior to transplant):

• Step 1 — Remote Pre-Screening (Before Travel): Submit medical records, echocardiography reports, cardiac catheterization data, and recent laboratory results to GAF Healthcare's medical team. A senior transplant cardiologist reviews eligibility within 48 hours.

• Step 2 — Arrival and Comprehensive Transplant Evaluation: Upon arrival in India or the UAE, the patient undergoes a 5–7 day structured evaluation: right heart catheterization, CPET, HLA typing and PRA testing, full organ function panel, psychosocial assessment, infectious disease screening, and multidisciplinary transplant committee (MTC) review.

• Step 3 — Listing and Waiting Period: Upon MTC approval, the patient is listed on the national/regional transplant registry (NOTTO in India; DOH Transplant Authority in the UAE). Wait time is unpredictable — days to months depending on blood type, body size, and donor availability. Patients requiring inotropic support or LVAD implantation may receive expedited listing priority.

• Step 4 — Bridge Therapy (If Required): Patients in hemodynamic decline may undergo HeartMate 3 LVAD implantation as a bridge to transplant, allowing safe waiting in a more stable clinical state.

PHASE 2 — TRANSPLANT SURGERY (Day 0):

• Donor heart identified → procurement team dispatched → cold ischemic time clock begins

• Recipient called in; pre-operative preparation: central venous access, arterial line, Swan-Ganz catheter, foley catheter, anesthesia induction (typically total IV anesthesia with opioid-based technique)

• Median sternotomy → initiation of cardiopulmonary bypass (CPB) on aorto-bicaval cannulation

• Cardiectomy performed, leaving recipient left atrial cuff and caval stumps

• Donor heart implanted using bicaval technique: sequential anastomosis (left atrium → IVC → SVC → pulmonary artery → ascending aorta)

• De-airing maneuvers → aortic cross-clamp removal → reperfusion

• Temporary pacing wires placed; hemodynamic assessment on CPB before weaning

• CPB weaned with inotropic support (typically dobutamine, milrinone ± vasopressors); right ventricular function carefully monitored — right heart failure is the most common immediate post-operative complication

• Total operative time: 4–8 hours

PHASE 3 — ICU RECOVERY (Days 1–7):

• Intubated and ventilated in the cardiac surgery ICU for 12–48 hours

• Hemodynamic monitoring via arterial line, pulmonary artery catheter: targeting MAP 70–80 mmHg, CI > 2.2 L/min/m², CVP 8–12 mmHg

• Immunosuppression initiated: tacrolimus, MMF, methylprednisolone

• Prophylactic antibiotic, antifungal (fluconazole), and antiviral (valganciclovir) therapy initiated

• Chest tubes removed by Day 2–4 once drainage subsides

• Gradual reduction in inotropic support as graft function stabilizes

• First endomyocardial biopsy (EMB) typically performed at Day 7–10

• Early ambulation begins under physiotherapy supervision: sitting at bedside by Day 3–4, standing by Day 5–6

PHASE 4 — GENERAL WARD RECOVERY (Days 8–21):

• Transfer out of ICU once hemodynamically stable, off vasoactive support, and breathing independently

• Daily wound care; sternal stability monitored (no sternal click or instability)

• Oral immunosuppression optimization; tacrolimus trough levels checked every 48 hours

• Rejection and infection surveillance continues: CBC, CRP, procalcitonin, tacrolimus levels, renal function daily

• Graded mobilization: corridor walking, stair climbing under cardiac rehabilitation physiotherapists

• Patient and caregiver education: immunosuppression adherence, infection precautions, wound care, early rejection symptom recognition, dietary restrictions (avoid grapefruit — CYP3A4 interaction with tacrolimus)

• Second EMB at Day 14

• Discharge planning: typically Day 14–21 post-transplant for stable, uncomplicated cases

PHASE 5 — OUTPATIENT FOLLOW-UP IN COUNTRY (Weeks 3–10):

• Weekly outpatient visits for first 6 weeks: clinical assessment, blood tests (tacrolimus trough, renal function, CBC, liver enzymes), EMB per protocol

• Echocardiogram at Week 2, 4, and 8 post-transplant

• Cardiac rehabilitation: formal, structured program 3× per week; progressive aerobic conditioning

• Immunosuppression dose titration based on trough levels and side-effect profile

• Vaccination planning: live vaccines permanently contraindicated; inactivated vaccines (influenza, pneumococcal, COVID-19) recommended from 3–6 months post-transplant

PHASE 6 — FIT-TO-FLY ASSESSMENT (Weeks 8–12):

• Minimum 8 weeks before intercontinental air travel is considered

• Fit-to-fly criteria: hemodynamically stable, no active rejection (biopsy-confirmed 1R or lower), no active infection, stable immunosuppression doses with consistent trough levels, adequate sternal healing (CT sternum if in doubt), eGFR stable, full understanding of emergency protocols

• GAF Healthcare arranges a detailed medical summary, 90-day medication supply, and emergency contact protocol for the receiving cardiologist in the patient's home country

• Minimum 10–12 weeks recommended for most intercontinental travelers (e.g., from Europe, North America, the Middle East) to allow adequate rejection biopsy surveillance completion

PHASE 7 — LONG-TERM MILESTONES:

• 3 months: Return to light daily activities; driving permitted in most jurisdictions (confirm locally)

• 6 months: Return to desk-based/light work; formal cardiac rehab completion

• 12 months: Annual coronary angiography + IVUS for CAV surveillance; comprehensive annual metabolic, renal, and malignancy screening

• Ongoing (lifelong): Immunosuppression is lifelong; compliance is non-negotiable. Annual skin cancer surveillance (squamous cell carcinoma incidence elevated 65–100× in immunosuppressed transplant patients). Annual CAV screening. Statin therapy (pravastatin or fluvastatin preferred — less CYP3A4 interaction) for all recipients.